Potential Role of Circulating microRNA-21 for Hepatocellular Carcinoma Diagnosis: A Meta-Analysis

Abstract

BackgroundCirculating microRNA-21 (miR-21) is known to be aberrantly expressed in hepatocellular carcinoma (HCC) patients, and this implies that microRNA-21 is a promising and novel indicator of HCC. However, a systematic evaluation of the performance of microRNA-21 as a diagnostic marker for HCC has yet to be conducted. Therefore, the test performance of circulating miR-21 for HCC was assessed in this study.MethodsThree common international databases and a Chinese electronic database were used to search for literature on the diagnostic accuracy of microRNA-21 for HCC. The pooled results included the sensitivity and specificity of microRNA-21 for HCC detection and were analyzed with a random effect model. The area under summary receiver operating characteristic curve (AUC) was used to estimate overall test performance.ResultsA total of 339 HCC patients and 338 controls without HCC from four published studies were eligible for the meta-analysis and included in our study. The test performance of circulating miR-21 in HCC detection was assessed with the summary estimates of sensitivity and specificity, which were 81.2% (95% CI: 70.8% to 88.4%) and 84.8% (95% CI: 75.1% to 91.2%), respectively. The value of AUC was 0.90 (95% CI: 0.87 to 0.92). Significant inter-study heterogeneity was detected by our analysis, and sub-group analyses suggested that the type of control group was probably a source of heterogeneity.ConclusionsOur current findings suggested that circulating miR-21 can serve as a potential co-biomarker for early-stage HCC diagnosis. Thorough large-scale studies are needed to confirm the generalizability of our findings.

Extracellular miRNA-21 as a novel biomarker in glioma: evidence from meta-analysis, clinical validation and experimental investigations

“…MiR-21, one of the most studied miRNAs, has been widely reported for its over-expression in various cancer types, and has also been found in extracellular environment [10, 12–14, 77]. In the present study, we performed a meta-analysis of 7494 participants derived from 81 published studies worldwide.…”

Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma

“…In addition, serum miR-21 levels are also increased in patients with different liver diseases, namely chronic viral hepatitis, as well as in other human cancers, such as gastric and colorectal cancer [ 112 , 113 ]. In fact, although increased expression of miR-21 may not be specifically associated with HCC alone, a recent study showed that circulating miR-21 may serve as a potential co-biomarker for early-stage HCC diagnosis [ 114 ]. Tomimaru et al also suggested that the combination of plasma miR-21 and AFP has a better differentiating power than miR-21 or AFP alone in discriminating HCC from healthy volunteers [ 111 ].…”

The potential value of microRNA-4463 in the prognosis evaluation in hepatocellular carcinoma

“… 51 At the same time, miR-21 had been confirmed to be regarded as a marker for early diagnosis of liver cancer. 52 Although there are a considerable number of studies on miRNAs in HCC, and it also shows the relationship between the diagnosis, metastasis and prognosis of HCC, but there is no report about the expression of miR-4463.…”